{"gene":"TIMP4","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":1997,"finding":"TIMP-4 binds specifically and with high affinity to the C-terminal hemopexin-like domain (C domain) of human progelatinase A (MMP-2), but not to the fibronectin type II-like collagen-binding domain. This interaction is similar to TIMP-2 binding to progelatinase A, and TIMP-2 and TIMP-4 compete for a common or overlapping binding site on the C domain.","method":"Microwell protein binding assay, affinity chromatography, competition binding assay with recombinant domains","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with recombinant proteins, multiple orthogonal binding assays, Kd determination, competition experiments","pmids":["9182583"],"is_preprint":false},{"year":1997,"finding":"Recombinant TIMP-4 inhibits MMP-1, MMP-2, MMP-3, MMP-7, and MMP-9 enzymatic activity with IC50 values of 19, 3, 45, 8, and 83 nM, respectively, and inhibits invasion of breast cancer cells across reconstituted basement membranes.","method":"Enzymatic kinetic inhibition assays with purified recombinant TIMP-4; Matrigel invasion assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro enzymatic inhibition assays with recombinant protein, multiple MMPs tested, functional invasion assay","pmids":["9252358"],"is_preprint":false},{"year":2000,"finding":"TIMP-4, unlike TIMP-2, does not support MT1-MMP-dependent activation of pro-MMP-2 on the cell surface, even though it is an efficient MT1-MMP inhibitor. TIMP-4 lacks the ability to form the TIMP-2-like ternary complex (MT1-MMP·TIMP·pro-MMP-2) required for pro-MMP-2 activation.","method":"Cell-based pro-MMP-2 activation assay; Timp2-null cell reconstitution; coexpression of MT1-MMP with TIMP-4 or TIMP-2","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-based functional assay in Timp2-null cells with genetic reconstitution, replicated across two studies (PMID 10998420, 11178970)","pmids":["10998420","11178970"],"is_preprint":false},{"year":2001,"finding":"TIMP-4 binds to MT1-MMP and inhibits its autocatalytic turnover/processing on the cell surface. When coexpressed with TIMP-2, TIMP-4 competitively reduces pro-MMP-2 activation by MT1-MMP, suggesting TIMP-4 competes with TIMP-2 for binding to MT1-MMP.","method":"Coexpression of MT1-MMP with TIMP-4 and/or TIMP-2 in cells; assessment of MT1-MMP autocatalytic processing and pro-MMP-2 activation by zymography/Western blot","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based coexpression assay, single lab, two functional readouts","pmids":["11178970"],"is_preprint":false},{"year":2001,"finding":"TIMP-4 blocks MT1-MMP-mediated activation of pro-MMP-2 (progelatinase A) in human umbilical vein endothelial cells, whereas TIMP-1 does not. TIMP-4 also reduces invasion of U251 glioma cells through Matrigel.","method":"Cell-based pro-MMP-2 activation assay with recombinant TIMP-4; Matrigel invasion assay with U87 cells overexpressing TIMP-4","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based functional assays, single lab, two orthogonal functional readouts","pmids":["11437402"],"is_preprint":false},{"year":2002,"finding":"Kinetic analysis shows TIMP-4 inhibits MMPs with association rate constants (~10^5 M^-1 s^-1) and Ki values (10^-9 to 10^-12 M) similar to TIMP-1 and TIMP-2. TIMP-4 retains higher inhibitory reactivity with MMPs at acidic pH compared to TIMP-1 and TIMP-2. Biosensor analysis reveals that both pro-MMP-2 and active MMP-2 (with blocked active site) have essentially identical affinities for TIMP-4 via a hemopexin domain site, while active MMP-2 also engages a second lower-affinity site through the catalytic domain.","method":"Progress curve kinetic analysis; alpha2-macroglobulin dissociation assay; IAsys biosensor analysis","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — rigorous in vitro kinetic reconstitution with recombinant proteins, multiple orthogonal methods (progress curves, dissociation assay, biosensor)","pmids":["12475252"],"is_preprint":false},{"year":2002,"finding":"TIMP-4 is the major MMP inhibitor in human platelets (12–16 ng per 10^8 platelets), co-localizes with MMP-2 in resting platelets, and is released upon platelet aggregation induced by collagen and thrombin. Recombinant TIMP-4 (but not TIMP-1) partially inhibits platelet aggregation and recruitment, and this inhibition is potentiated by NO donor GSNO.","method":"Western blot, reverse zymography, immunogold electron microscopy, aggregometry, flow cytometry, serotonin release assay","journal":"British journal of pharmacology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods, direct functional assays with recombinant TIMP-4, subcellular localization established","pmids":["12466243"],"is_preprint":false},{"year":2002,"finding":"The Timp-4 promoter contains an initiator-like element and an Sp1 motif that are essential for expression; mutation of either element almost completely abolishes reporter expression. An inverted CCAAT box acts as a modest repressor (2-fold increase when mutated). The TATA-less promoter is non-inducible by serum.","method":"Transient transfection reporter assays with promoter deletion and point mutants in C3H10T1/2 fibroblasts; RACE and RNase protection for transcription start site mapping","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — functional promoter mutagenesis with reporter assays, multiple mutants tested, single lab","pmids":["11988080"],"is_preprint":false},{"year":1999,"finding":"TIMP-4 protein accumulates in the adventitia and neointima of rat carotid arteries after balloon injury, and recombinant TIMP-4 reduces invasion of rat vascular smooth muscle cells through matrix-coated membranes by 53%, implicating TIMP-4 in controlling smooth muscle cell migration and collagen deposition after vascular injury.","method":"In situ hybridization, immunohistochemistry, Western blot of injured arteries; in vitro Boyden chamber invasion assay with recombinant TIMP-4","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization in vivo with functional consequence validated in vitro, single lab","pmids":["10082471"],"is_preprint":false},{"year":2003,"finding":"Adenoviral gene transfer of TIMP-4 into rat carotid arteries after balloon injury inhibits vascular smooth muscle cell migration in vitro and reduces neointimal hyperplasia by 66.5% compared to controls at 28 days.","method":"Adenovirus-mediated gene transfer in vivo; monolayer scrape migration assay in vitro; morphometric analysis of neointima/media ratio","journal":"Beijing da xue xue bao. Yi xue ban","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct loss/gain-of-function experiment in vivo and in vitro, single lab","pmids":["12947565"],"is_preprint":false},{"year":2005,"finding":"The N-terminal domain of TIMP-4 (N-TIMP-4) is a slow tight-binding inhibitor of TACE (ADAM-17) with low nanomolar affinity, whereas full-length TIMP-4 has negligible activity against TACE. Transplantation of three residues (Pro-Phe-Gly) from TIMP-3's AB-loop onto N-TIMP-4 enhanced TACE inhibition 10-fold, indicating the C-terminal domain suppresses and specific AB-loop residues determine TACE activity.","method":"Kinetic inhibition assays with recombinant N-TIMP-4 and full-length TIMP-4 against TACE; site-directed mutagenesis of AB-loop and EF-loop","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic assay with mutagenesis identifying specific residues, multiple mutants tested","pmids":["15713681"],"is_preprint":false},{"year":2010,"finding":"Timp4-deficient mice (Timp4−/−) generated by homologous recombination show significantly increased post-myocardial infarction mortality primarily due to left ventricular rupture. This enhanced mortality is rescued by a synthetic MMP inhibitor or by genetic deletion of Mmp2, demonstrating that TIMP4 functions as an MMP inhibitor (specifically MMP-2) after myocardial infarction. After cardiac pressure overload, Timp4-deficiency is compensated by increased Timp2 expression with no survival difference.","method":"Homologous recombination knockout; myocardial infarction model; aortic banding model; synthetic MMP inhibitor treatment; genetic cross with Mmp2-/- mice; cardiac function assessment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (Timp4-/- × Mmp2-/- double knockout rescue), replicated by pharmacological rescue, multiple disease models","pmids":["20516072"],"is_preprint":false},{"year":2010,"finding":"MMP-9 treatment of primary cardiomyocytes attenuates voltage-induced contraction and reduces Ca2+ transients; TIMP-4 (an MMP-9 inhibitor) reverses this inhibition, and this MMP-9 effect is mediated through PAR-1 signaling. MMP-9 knockout cardiomyocytes contract more rapidly and release more Ca2+ than controls, associated with induction of serca-2a.","method":"Primary cardiomyocyte isolation; video-edge detection contractility assay; Fura-2-AM calcium imaging; MMP-9 KO mice; PAR-1 antagonist; recombinant TIMP-4 treatment","journal":"Cell biochemistry and biophysics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional assay with recombinant TIMP-4 in primary cells, MMP-9 KO confirmation, single lab","pmids":["20422465"],"is_preprint":false},{"year":2013,"finding":"Hypoxia upregulates TIMP-4 (and TIMP-3) in fetal rat hearts and H9c2 cardiomyocytes. Knockdown of TIMP-4 completely abrogates hypoxia-mediated inhibition of cardiomyocyte proliferation (Ki-67, BrdU, cyclin D2), while having no significant effect on basal proliferation, establishing a causal role for TIMP-4 in hypoxia-induced inhibition of cardiomyocyte proliferation.","method":"siRNA knockdown of TIMP-4 in H9c2 cells; Ki-67 immunostaining; BrdU incorporation; Western blot for cyclin D2 and p27; ex vivo fetal heart hypoxia model","journal":"American journal of physiology. Regulatory, integrative and comparative physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA loss-of-function with specific proliferation readouts, two model systems, single lab","pmids":["23427085"],"is_preprint":false},{"year":2015,"finding":"TIMP-4 overexpression in cervical cancer cells enriches the tumor progenitor cell (TPC) population and accelerates xenograft tumor growth. Genome-wide expression analysis shows hrTIMP-4 treatment activates NFκB signaling pathway globally, modulating cell survival, proliferation, inflammation, and EMT networks.","method":"Stable TIMP-4 overexpression; xenograft limiting dilution assay; recombinant TIMP-4 treatment; microarray gene expression; in silico pathway analysis; NFκB pathway validation","journal":"Molecular carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — stable gain-of-function with in vivo and in vitro readouts, pathway analysis, single lab","pmids":["26618609"],"is_preprint":false},{"year":2015,"finding":"TIMP-4 knockdown in 3T3-L1 preadipocytes accelerates differentiation into mature adipocytes, associated with decreased NFκB activity during adipogenesis, suggesting TIMP-4 acts as a negative regulator of adipogenesis via NFκB modulation.","method":"Stable shRNA knockdown in 3T3-L1 cells; adipocyte differentiation assay; microarray gene expression; NFκB activity assay","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — stable loss-of-function with functional differentiation readout and pathway identification, single lab","pmids":["25999146"],"is_preprint":false},{"year":2016,"finding":"LOX (lysyl oxidase) transcriptionally activates the SNAI2 promoter, and LOX/SNAI2 depletion reduces TIMP4 secretion in cancer cell lines. LOX binds to the SNAI2 promoter as shown by chromatin immunoprecipitation, placing TIMP4 downstream of a LOX-SNAI2 axis.","method":"Chromatin immunoprecipitation (ChIP); promoter luciferase assay; siRNA knockdown; protein array for MMPs/TIMPs; in vivo metastatic mouse model","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and luciferase assays establish LOX→SNAI2 axis, TIMP4 secretion downstream confirmed by array, single lab","pmids":["27029493"],"is_preprint":false},{"year":2016,"finding":"Recombinant TIMP-4 treatment of MCF7 breast cancer cells activates ER-α signaling (increases ER-α protein levels) and enriches for ER-α binding sites in promoters of TIMP4-upregulated genes. TIMP-4 also modulates HIF1A and TGF-β signaling while downregulating FOXO3 signaling.","method":"Recombinant TIMP-4 treatment; RNASeq; RT-PCR validation; network pathway analysis","journal":"Folia biologica","confidence":"Low","confidence_rationale":"Tier 3 / Weak — transcriptomic analysis after recombinant protein treatment, single method, single lab, limited mechanistic follow-up","pmids":["27187039"],"is_preprint":false},{"year":2017,"finding":"Absence of TIMP4 in knockout mice impairs lipid absorption on high-fat diet by preventing proteolytic processing of CD36 protein in intestinal enterocytes. HFD increases CD36 protein (not mRNA) in WT but not Timp4-/- intestinal enterocytes, indicating TIMP4 regulates CD36 post-translationally through metalloproteinase-dependent mechanisms.","method":"Timp4 knockout mice; high-fat diet model; CD36 protein and mRNA quantification in intestinal enterocytes; lipid absorption (fecal free fatty acid); body composition analysis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with post-translational mechanism inference (protein/mRNA dissociation), single lab, multiple readouts","pmids":["28740132"],"is_preprint":false},{"year":2019,"finding":"CRN2 (an actin filament binding protein) directly binds TIMP4 and MMP14 (MT1-MMP) as novel binding partners; all three proteins co-localize at lamellipodia fronts. CRN2 increases TIMP4 secretion and enhances MMP14 catalytic activity, promoting perivascular invasion of glioblastoma cells.","method":"Immunoprecipitation; pull-down assays; enzyme activity assay; immunofluorescence co-localization; CRN2 knockout mouse model; transplanted glioblastoma cell assay","journal":"European journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP/pulldown with functional readout (secretion, enzyme activity), single lab","pmids":["31677819"],"is_preprint":false},{"year":2015,"finding":"TGF-β1 stimulation of isolated human atrial fibroblasts directly suppresses TIMP-4 protein levels as shown by Western blot. In patients with atrial fibrillation secondary to rheumatic heart disease, TIMP-4 expression is inversely correlated with TGF-β1 levels (r = -0.98), and lower TIMP-4 correlates with increased MMP-2, collagen I, and collagen III.","method":"In vitro recombinant TGF-β1 stimulation of primary atrial fibroblasts; Western blot; patient tissue Western blot and qRT-PCR; Masson staining","journal":"Molecular and cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct in vitro stimulation assay plus clinical tissue correlation, single lab","pmids":["25971370"],"is_preprint":false},{"year":2022,"finding":"EZH2 suppresses Timp4 gene transcription by catalyzing H3K27me3 modifications in the Timp4 promoter region. Knockdown of Ezh2 increases Timp4 expression and accelerates replicative senescence of atrial fibroblasts; Ezh2 overexpression reduces senescence. A functional balance between TIMP4 and MMP8 in atrial fibroblasts is disrupted by Ezh2 level changes.","method":"ChIP assay for H3K27me3 at Timp4 promoter; siRNA knockdown and overexpression of Ezh2; senescence assays; RNA-seq; GSK-126 and GSK-343 methyltransferase inhibitors","journal":"Journal of inflammation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP establishes direct epigenetic mark on Timp4 promoter, gain/loss-of-function with functional readout, single lab","pmids":["35996686"],"is_preprint":false},{"year":2021,"finding":"miR-146b-5p directly targets and represses TIMP4 in atrial cardiomyocytes; reduced TIMP4 increases MMP9 activity and collagen synthesis. Inhibition of miR-146b-5p in a MI mouse model increases TIMP4 expression and reduces cardiac fibrosis markers (MMP9, TGFB1, COL1A1).","method":"miR-146b-5p transfection in hiPSC-aCMs-fibroblast co-culture; antagomiR-146 treatment in MI mouse model; Western blot and qRT-PCR for TIMP4/MMP9/TGFB1/COL1A1","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — miRNA overexpression/inhibition with functional collagen/MMP readout in vitro and in vivo, single lab","pmids":["34643044"],"is_preprint":false},{"year":2023,"finding":"Loss of TIMP4 does not exacerbate thoracic or abdominal aortic aneurysm severity compared to wild-type mice, whereas loss of TIMP3 significantly worsens both. In vitro, Timp4 knockdown does not significantly compromise endothelial monolayer permeability compared to Timp3 knockdown.","method":"Timp4-/- and Timp3-/- mouse aortic aneurysm models (elastase); histology; proteinase activity; EC monolayer permeability assay","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — negative finding for TIMP4 in aneurysm established by KO experiment, provides pathway context; single lab","pmids":["37844423"],"is_preprint":false},{"year":2016,"finding":"TIMP4 promoter CpG islands undergo methylation during heart failure progression (created by AV fistula), leading to epigenetic silencing of TIMP4 expression. Upregulation of miR-122a also contributes to TIMP4 regulation. Consequent MMP9 upregulation drives cardiac remodeling.","method":"Methylation-specific PCR; high-resolution melting; bisulfite sequencing; ChIP for histone modifications; miRNA expression analysis; AV fistula heart failure mouse model; echocardiography","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methylation assays plus ChIP establish epigenetic mechanism, single lab","pmids":["27396717"],"is_preprint":false},{"year":2025,"finding":"AKAP1 (RNA binding protein) stabilizes TIMP-4 mRNA to maintain TIMP-4 expression. TIMP-4 upregulation suppresses Ang-II-induced NF-κB pathway activation, oxidative stress, inflammation, and MMP9 expression in vascular smooth muscle cells. TIMP-4 reduction partially abrogates AKAP1's suppressive effects, placing TIMP-4 downstream of AKAP1 in protection against VSMC injury.","method":"RNA immunoprecipitation (RIP); mRNA stability analysis; TIMP-4 overexpression and knockdown in VSMCs; Western blot for NF-κB signaling; oxidative stress and inflammation assays; GSE7084 and GSE140947 dataset analysis","journal":"Shock (Augusta, Ga.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RIP establishes AKAP1-TIMP4 mRNA interaction, gain/loss-of-function with NF-κB pathway readout, single lab","pmids":["39965635"],"is_preprint":false},{"year":2023,"finding":"TIMP4 heterozygous loss-of-function variants (c.528C>A and c.234_235insAA) are enriched in early-onset high myopia patients. Timp4-deficient rats show axial length elongation, reduced retinal and scleral collagen content, and reduced retinal thickness in a dose-dependent manner (Timp4-/- < Timp4+/- < Timp4+/+), establishing a causal role for TIMP4 in maintaining ocular ECM homeostasis and normal ocular development.","method":"Whole exome sequencing; Timp4 gene-editing rat model; ocular morphology and axial length measurement; electroretinogram; HE and immunofluorescence staining; collagen quantification; form deprivation myopia model","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO rat model with dose-dependent phenotype and multiple ocular readouts, supported by human genetic data, single lab","pmids":["38069250"],"is_preprint":false},{"year":2006,"finding":"In human endometrium, TIMP-4 mRNA is exclusively produced in stromal cells, while TIMP-4 protein is taken up by epithelial cells, accumulates in apical granules, and is secreted into uterine fluid. TIMP-4 is the main TIMP present in uterine fluid. This stromal-to-epithelial transcytosis pathway establishes compartment-specific regulation of MMP-26 activity.","method":"In situ hybridization; immunohistochemistry; real-time PCR on separated stromal and epithelial cells; Western blot of uterine fluid","journal":"Molecular human reproduction","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct subcellular localization in separated cell populations with functional implications, single lab","pmids":["16809379"],"is_preprint":false},{"year":2013,"finding":"Osteoprotegerin (OPG) upregulates TIMP-4 expression while downregulating ADAMTS-5 in chondrocytes via MEK/ERK signaling; suppression of ERK by PD098059 blocks OPG-induced TIMP-4 upregulation. OPG had no effect on TIMP-1, TIMP-2, or TIMP-3 expression, showing specificity for TIMP-4.","method":"Primary rat chondrocyte culture; OPG treatment; MEK/ERK inhibitors (U0126, PD098059); Western blot; qPCR","journal":"Molecular medicine reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway inhibitor experiments establish MEK/ERK as upstream of TIMP-4 regulation, specific to TIMP-4 vs other TIMPs, single lab","pmids":["24126801"],"is_preprint":false}],"current_model":"TIMP-4 is a secreted metalloproteinase inhibitor that directly inhibits MMP-1, -2, -3, -7, -9, and MT1-MMP (MMP-14), and weakly inhibits TACE (ADAM-17) only in its N-terminal domain form; it binds the hemopexin C-domain of pro-MMP-2 (similar to TIMP-2) but, unlike TIMP-2, cannot form the ternary MT1-MMP·TIMP·pro-MMP-2 complex required for pro-MMP-2 activation and instead competitively inhibits this process; in the heart it is essential post-myocardial infarction through MMP-2 inhibition (rescued by MMP-2 deletion), is epigenetically silenced by promoter CpG methylation (via Ezh2/H3K27me3) and miR-122a in heart failure, and regulates immune balance via exosomal delivery; it controls vascular smooth muscle cell migration and neointimal formation after injury; in platelets it is the dominant MMP inhibitor and modulates aggregation; its expression is transcriptionally driven by an Sp1/initiator element, regulated downstream of LOX-SNAI2, suppressed by TGF-β1, and its mRNA is stabilized by AKAP1; in adipocytes and cardiomyocytes TIMP-4 acts as a negative regulator of differentiation/proliferation partly through NFκB signaling; and its loss disrupts CD36 proteolytic processing in intestinal enterocytes to impair lipid absorption."},"narrative":{"mechanistic_narrative":"TIMP4 is a secreted tissue inhibitor of metalloproteinases that restrains MMP-driven extracellular matrix turnover across cardiovascular, vascular, reproductive, and ocular tissues [PMID:9252358, PMID:20516072]. It is a broad-spectrum, high-affinity inhibitor of soluble MMPs (MMP-1, -2, -3, -7, -9) with low-nanomolar potency [PMID:9252358, PMID:12475252], and binds the C-terminal hemopexin-like domain of pro-MMP-2 at a site overlapping that of TIMP-2 [PMID:9182583, PMID:12475252]. Despite being an efficient MT1-MMP inhibitor, TIMP-4 cannot assemble the TIMP-2-like ternary MT1-MMP·TIMP·pro-MMP-2 complex needed for cell-surface pro-MMP-2 activation, and instead competes with TIMP-2 to suppress this activation step [PMID:10998420, PMID:11178970, PMID:11437402]. The inhibitory repertoire is domain-partitioned: only the N-terminal domain inhibits TACE/ADAM-17, an activity suppressed by the C-terminal domain and tunable by AB-loop residues [PMID:15713681]. In the heart, TIMP4 is essential after myocardial infarction, where its loss causes lethal ventricular rupture that is rescued by Mmp2 deletion, establishing MMP-2 inhibition as its core protective mechanism [PMID:20516072]. Its expression is governed by an Sp1/initiator-driven TATA-less promoter [PMID:11988080] and is dynamically controlled by epigenetic silencing through promoter CpG methylation and EZH2/H3K27me3 [PMID:35996686, PMID:27396717], by miRNA repression [PMID:34643044, PMID:27396717], by suppression downstream of TGF-β1 [PMID:25971370], and by mRNA stabilization through AKAP1 [PMID:39965635]; downstream, TIMP-4 modulates NFκB signaling in vascular smooth muscle cells and during adipogenesis [PMID:25999146, PMID:39965635]. Beyond MMP inhibition, TIMP4 controls vascular smooth muscle cell migration and neointimal formation after injury [PMID:10082471, PMID:12947565], regulates CD36 proteolytic processing in enterocytes to enable lipid absorption [PMID:28740132], and maintains ocular ECM homeostasis, with heterozygous loss-of-function variants linked to early-onset high myopia [PMID:38069250].","teleology":[{"year":1997,"claim":"Established that TIMP-4 is a functional MMP inhibitor and defined its physical interaction with pro-MMP-2, answering whether the protein behaves like other TIMPs.","evidence":"Recombinant binding/competition assays with MMP-2 domains and enzymatic inhibition assays plus a Matrigel invasion readout","pmids":["9182583","9252358"],"confidence":"High","gaps":["Inhibitory profile against membrane-type MMPs not yet tested","No in vivo confirmation of inhibitory function"]},{"year":2000,"claim":"Resolved why TIMP-4 differs functionally from TIMP-2 despite similar binding, showing it inhibits MT1-MMP but cannot support ternary-complex-dependent pro-MMP-2 activation.","evidence":"Cell-based pro-MMP-2 activation assays in Timp2-null cells with MT1-MMP/TIMP coexpression","pmids":["10998420","11178970","11437402"],"confidence":"High","gaps":["Structural basis for the failure to form the ternary complex not defined","Competition with TIMP-2 quantified only in overexpression systems"]},{"year":2002,"claim":"Provided rigorous kinetic constants and a two-site binding model, and identified platelets as a major physiological compartment for TIMP-4.","evidence":"Progress-curve kinetics and biosensor analysis with recombinant proteins; platelet biochemistry, electron microscopy and aggregometry","pmids":["12475252","12466243"],"confidence":"High","gaps":["Physiological relevance of the acidic-pH reactivity not established","Mechanism of TIMP-4 effect on platelet aggregation beyond MMP inhibition unclear"]},{"year":2002,"claim":"Defined the cis-elements controlling TIMP4 transcription, answering how the gene is constitutively expressed.","evidence":"Promoter deletion/point-mutant reporter assays and transcription start site mapping in fibroblasts","pmids":["11988080"],"confidence":"High","gaps":["Trans-acting factors beyond Sp1 not identified","No link yet to tissue-specific or signal-driven regulation"]},{"year":2005,"claim":"Mapped the domain determinants of TIMP-4 target specificity, showing the N-terminal domain alone inhibits TACE and that the C-terminal domain suppresses this.","evidence":"Kinetic inhibition assays of N-TIMP-4 versus full-length TIMP-4 against TACE with AB/EF-loop mutagenesis","pmids":["15713681"],"confidence":"High","gaps":["Physiological relevance of TACE inhibition by an N-terminal fragment in vivo unknown","Whether full-length TIMP-4 ever exposes this activity in tissue not addressed"]},{"year":2010,"claim":"Demonstrated the essential, MMP-2-specific cardioprotective role of TIMP4 in vivo through genetic epistasis, the strongest causal anchor for its function.","evidence":"Timp4 knockout mice in MI and pressure-overload models with pharmacological and Mmp2-deletion rescue; primary cardiomyocyte contractility assays","pmids":["20516072","20422465"],"confidence":"High","gaps":["Whether other tissues show MMP-2-specific dependence not tested","Compensation by TIMP-2 leaves the unique role outside the heart unclear"]},{"year":2016,"claim":"Established that TIMP4 expression is dynamically silenced in cardiac and vascular disease through layered epigenetic and post-transcriptional mechanisms.","evidence":"Methylation-specific PCR, bisulfite sequencing, ChIP for H3K27me3, miRNA profiling and EZH2 gain/loss-of-function in heart-failure and atrial-fibroblast models","pmids":["27396717","35996686","34643044","25971370"],"confidence":"Medium","gaps":["Causal hierarchy among methylation, EZH2, and miRNAs not resolved","Most mechanisms shown in single labs and rodent models"]},{"year":2017,"claim":"Extended TIMP4 function beyond MMP inhibition to metabolic physiology, showing it is required for CD36 proteolytic processing and intestinal lipid absorption.","evidence":"Timp4 knockout mice on high-fat diet with CD36 protein/mRNA dissociation and lipid absorption measurements","pmids":["28740132"],"confidence":"Medium","gaps":["The specific metalloproteinase mediating CD36 processing not identified","Direct enzymatic mechanism linking TIMP-4 to CD36 not reconstituted"]},{"year":2019,"claim":"Identified a direct protein partner (CRN2) linking TIMP-4 and MT1-MMP at the invasive front, suggesting spatial coordination of inhibitor and protease.","evidence":"Reciprocal Co-IP/pull-down, enzyme activity assays and co-localization in glioblastoma cells with a CRN2 knockout model","pmids":["31677819"],"confidence":"Medium","gaps":["Single lab; reciprocal validation not extended to other systems","Functional consequence of the CRN2-TIMP4 interaction on inhibitory activity unclear"]},{"year":2023,"claim":"Connected TIMP4 to a human Mendelian-like phenotype, establishing a causal role in ocular ECM homeostasis.","evidence":"Whole-exome sequencing of high-myopia patients plus dose-dependent Timp4-deficient rat ocular phenotyping","pmids":["38069250"],"confidence":"Medium","gaps":["Molecular target whose dysregulation drives scleral/retinal collagen loss not defined","Human variants are heterozygous; full penetrance and mechanism not established"]},{"year":2025,"claim":"Defined an mRNA-stabilizing upstream regulator (AKAP1) and placed TIMP-4 as a node suppressing NFκB-driven vascular injury responses.","evidence":"RNA immunoprecipitation, mRNA stability assays and TIMP-4 gain/loss-of-function with NFκB pathway readouts in VSMCs","pmids":["39965635"],"confidence":"Medium","gaps":["Direct mechanism of NFκB suppression by TIMP-4 not resolved","Single lab; in vivo confirmation of the AKAP1-TIMP4 axis lacking"]},{"year":null,"claim":"How TIMP-4's varied non-canonical activities (CD36 processing, NFκB modulation, platelet and ocular roles) connect mechanistically to its core metalloproteinase-inhibitory function remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model explaining ternary-complex failure versus TIMP-2","Tissue-specific MMP substrates downstream of TIMP-4 largely uncharacterized","Whether NFκB and metabolic effects are protease-dependent unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,5,11]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1,10]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[6,27]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,3]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[8,26]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[18]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[15,25]}],"complexes":[],"partners":["MMP2","MMP14","TIMP2","ADAM17","MMP9","CRN2","AKAP1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q99727","full_name":"Metalloproteinase inhibitor 4","aliases":["Tissue inhibitor of metalloproteinases 4","TIMP-4"],"length_aa":224,"mass_kda":25.5,"function":"Complexes with metalloproteinases (such as collagenases) and irreversibly inactivates them by binding to their catalytic zinc cofactor. Known to act on MMP-1, MMP-2, MMP-3, MMP-7 and MMP-9","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q99727/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TIMP4","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TIMP4","total_profiled":1310},"omim":[{"mim_id":"621295","title":"CEREBRAL ARTERIOPATHY, AUTOSOMAL RECESSIVE, WITH SUBCORTICAL INFARCTS AND LEUKOENCEPHALOPATHY 1; CARASIL1","url":"https://www.omim.org/entry/621295"},{"mim_id":"601915","title":"TISSUE INHIBITOR OF METALLOPROTEINASE 4; TIMP4","url":"https://www.omim.org/entry/601915"},{"mim_id":"600755","title":"SYNAPSIN II; SYN2","url":"https://www.omim.org/entry/600755"},{"mim_id":"600276","title":"NOTCH RECEPTOR 3; NOTCH3","url":"https://www.omim.org/entry/600276"},{"mim_id":"188826","title":"TISSUE INHIBITOR OF METALLOPROTEINASE 3; TIMP3","url":"https://www.omim.org/entry/188826"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":229.4},{"tissue":"breast","ntpm":171.9}],"url":"https://www.proteinatlas.org/search/TIMP4"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q99727","domains":[{"cath_id":"2.40.50.120","chopping":"46-140","consensus_level":"medium","plddt":95.7576,"start":46,"end":140},{"cath_id":"3.90.370.10","chopping":"142-215","consensus_level":"medium","plddt":91.6938,"start":142,"end":215}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99727","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99727-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99727-F1-predicted_aligned_error_v6.png","plddt_mean":88.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TIMP4","jax_strain_url":"https://www.jax.org/strain/search?query=TIMP4"},"sequence":{"accession":"Q99727","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99727.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99727/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99727"}},"corpus_meta":[{"pmid":"9013889","id":"PMC_9013889","title":"Murine tissue inhibitor of metalloproteinases-4 (Timp-4): cDNA isolation and expression in adult mouse tissues.","date":"1997","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9013889","citation_count":167,"is_preprint":false},{"pmid":"9182583","id":"PMC_9182583","title":"Specific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal hemopexin-like domain of human gelatinase A. TIMP-4 binds progelatinase A and the COOH-terminal domain in a similar manner to TIMP-2.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9182583","citation_count":129,"is_preprint":false},{"pmid":"10998420","id":"PMC_10998420","title":"Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10998420","citation_count":109,"is_preprint":false},{"pmid":"9252358","id":"PMC_9252358","title":"Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4).","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9252358","citation_count":105,"is_preprint":false},{"pmid":"11437402","id":"PMC_11437402","title":"Differential expression and localization of TIMP-1 and TIMP-4 in human gliomas.","date":"2001","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11437402","citation_count":73,"is_preprint":false},{"pmid":"20516072","id":"PMC_20516072","title":"Mice with tissue inhibitor of metalloproteinases 4 (Timp4) deletion succumb to induced myocardial infarction but not to cardiac pressure overload.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20516072","citation_count":73,"is_preprint":false},{"pmid":"11178970","id":"PMC_11178970","title":"Differential roles of TIMP-4 and TIMP-2 in pro-MMP-2 activation by MT1-MMP.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11178970","citation_count":69,"is_preprint":false},{"pmid":"16521002","id":"PMC_16521002","title":"Tissue inhibitor of metalloproteinases 4 (TIMP4) is involved in inflammatory processes of human cardiovascular pathology.","date":"2006","source":"Histochemistry and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16521002","citation_count":66,"is_preprint":false},{"pmid":"12466243","id":"PMC_12466243","title":"Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP-4) in human platelets.","date":"2002","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12466243","citation_count":66,"is_preprint":false},{"pmid":"12475252","id":"PMC_12475252","title":"E. coli expression of TIMP-4 and comparative kinetic studies with TIMP-1 and TIMP-2: insights into the interactions of TIMPs and matrix metalloproteinase 2 (gelatinase A).","date":"2002","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12475252","citation_count":60,"is_preprint":false},{"pmid":"27029493","id":"PMC_27029493","title":"Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers.","date":"2016","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/27029493","citation_count":58,"is_preprint":false},{"pmid":"11988080","id":"PMC_11988080","title":"Identification of an initiator-like element essential for the expression of the tissue inhibitor of metalloproteinases-4 (Timp-4) gene.","date":"2002","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/11988080","citation_count":56,"is_preprint":false},{"pmid":"10082471","id":"PMC_10082471","title":"TIMP-4 is regulated by vascular injury in rats.","date":"1999","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/10082471","citation_count":55,"is_preprint":false},{"pmid":"15713681","id":"PMC_15713681","title":"Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting: fine-tuning TIMP-4 for optimal inhibition of tumor necrosis factor-{alpha}-converting enzyme.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15713681","citation_count":49,"is_preprint":false},{"pmid":"17873896","id":"PMC_17873896","title":"Increased expression of matrix metalloproteinases-21 and -26 and TIMP-4 in pancreatic adenocarcinoma.","date":"2007","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/17873896","citation_count":41,"is_preprint":false},{"pmid":"16940965","id":"PMC_16940965","title":"Coordinated peak expression of MMP-26 and TIMP-4 in preinvasive human prostate tumor.","date":"2006","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/16940965","citation_count":39,"is_preprint":false},{"pmid":"20422465","id":"PMC_20422465","title":"MMP-9 gene ablation and TIMP-4 mitigate PAR-1-mediated cardiomyocyte dysfunction: a plausible role of dicer and miRNA.","date":"2010","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/20422465","citation_count":37,"is_preprint":false},{"pmid":"30891826","id":"PMC_30891826","title":"Upregulated long noncoding RNA Linc00261 in pre-eclampsia and its effect on trophoblast invasion and migration via regulating miR-558/TIMP4 signaling pathway.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30891826","citation_count":36,"is_preprint":false},{"pmid":"28740132","id":"PMC_28740132","title":"Absence of Tissue Inhibitor of Metalloproteinase-4 (TIMP4) ameliorates high fat diet-induced obesity in mice due to defective lipid absorption.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28740132","citation_count":35,"is_preprint":false},{"pmid":"34643044","id":"PMC_34643044","title":"MicroRNA-146b-5p promotes atrial fibrosis in atrial fibrillation by repressing TIMP4.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34643044","citation_count":32,"is_preprint":false},{"pmid":"23427085","id":"PMC_23427085","title":"Hypoxia inhibits cardiomyocyte proliferation in fetal rat hearts via upregulating TIMP-4.","date":"2013","source":"American journal of physiology. Regulatory, integrative and comparative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/23427085","citation_count":31,"is_preprint":false},{"pmid":"12151094","id":"PMC_12151094","title":"Characterization of the murine Timp4 gene, localization within intron 5 of the synapsin 2 gene and tissue distribution of the mRNA.","date":"2002","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12151094","citation_count":29,"is_preprint":false},{"pmid":"22018271","id":"PMC_22018271","title":"Heterogeneity and degree of TIMP4, GATA4, SOX18, and EGFL7 gene promoter methylation in non-small cell lung cancer and surrounding tissues.","date":"2011","source":"Cancer genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22018271","citation_count":29,"is_preprint":false},{"pmid":"9693046","id":"PMC_9693046","title":"Cloning of the human tissue inhibitor of metalloproteinase-4 gene (TIMP4) and localization of the TIMP4 and Timp4 genes to human chromosome 3p25 and mouse chromosome 6, respectively.","date":"1998","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9693046","citation_count":27,"is_preprint":false},{"pmid":"26618609","id":"PMC_26618609","title":"Tissue inhibitor of metalloproteinases-4 (TIMP-4) regulates stemness in cervical cancer cells.","date":"2015","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/26618609","citation_count":25,"is_preprint":false},{"pmid":"31143784","id":"PMC_31143784","title":"Expressions of MMP-12, TIMP-4, and Neutrophil Elastase in PBMCs and Exhaled Breath Condensate in Patients with COPD and Their Relationships with Disease Severity and Acute Exacerbations.","date":"2019","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/31143784","citation_count":23,"is_preprint":false},{"pmid":"25971370","id":"PMC_25971370","title":"TGF-β1 and TIMP-4 regulate atrial fibrosis in atrial fibrillation secondary to rheumatic heart disease.","date":"2015","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25971370","citation_count":23,"is_preprint":false},{"pmid":"21858729","id":"PMC_21858729","title":"Matrix metalloproteinase-1 expression enhances tumorigenicity as well as tumor-related angiogenesis and is inversely associated with TIMP-4 expression in a model of glioblastoma.","date":"2011","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21858729","citation_count":21,"is_preprint":false},{"pmid":"15273280","id":"PMC_15273280","title":"Endometrial TIMP-4 mRNA is high at midcycle and in hyperplasia, but down-regulated in malignant tumours. Coordinated expression with MMP-26.","date":"2004","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/15273280","citation_count":20,"is_preprint":false},{"pmid":"35996686","id":"PMC_35996686","title":"Ezh2 Inhibits Replicative Senescence of Atrial Fibroblasts Through Promotion of H3K27me3 in the Promoter Regions of CDKN2a and Timp4 Genes.","date":"2022","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/35996686","citation_count":19,"is_preprint":false},{"pmid":"28028835","id":"PMC_28028835","title":"TIMP4 expression is regulated by miR-200b-3p in prostate cancer cells.","date":"2016","source":"APMIS : acta pathologica, microbiologica, et immunologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/28028835","citation_count":18,"is_preprint":false},{"pmid":"27396717","id":"PMC_27396717","title":"Epigenetic silencing of TIMP4 in heart failure.","date":"2016","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27396717","citation_count":18,"is_preprint":false},{"pmid":"24126801","id":"PMC_24126801","title":"Osteoprotegerin promotes the proliferation of chondrocytes and affects the expression of ADAMTS-5 and TIMP-4 through MEK/ERK signaling.","date":"2013","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/24126801","citation_count":16,"is_preprint":false},{"pmid":"36587888","id":"PMC_36587888","title":"Targeting interleukin-21 inhibits stress overload-induced cardiac remodelling via the TIMP4/MMP9 signalling pathway.","date":"2022","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36587888","citation_count":15,"is_preprint":false},{"pmid":"19048177","id":"PMC_19048177","title":"Promoter polymorphism (rs3755724, -55C/T) of tissue inhibitor of metalloproteinase 4 (TIMP4) as a risk factor for Kawasaki disease with coronary artery lesions in a Korean population.","date":"2008","source":"Pediatric cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/19048177","citation_count":13,"is_preprint":false},{"pmid":"24903383","id":"PMC_24903383","title":"TIMP-3 -1296 T>C and TIMP-4 -55 T>C gene polymorphisms play a role in the susceptibility of hepatocellular carcinoma among women.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24903383","citation_count":13,"is_preprint":false},{"pmid":"18301898","id":"PMC_18301898","title":"Association of TIMP-4 gene polymorphism with the risk of osteoarthritis in the Korean population.","date":"2008","source":"Rheumatology international","url":"https://pubmed.ncbi.nlm.nih.gov/18301898","citation_count":12,"is_preprint":false},{"pmid":"31677819","id":"PMC_31677819","title":"CRN2 binds to TIMP4 and MMP14 and promotes perivascular invasion of glioblastoma cells.","date":"2019","source":"European journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/31677819","citation_count":11,"is_preprint":false},{"pmid":"33537254","id":"PMC_33537254","title":"Zingerone Attenuates Pi-induced Vascular Calcification via AMPK-mediated TIMP4 Expression.","date":"2020","source":"Journal of lipid and atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/33537254","citation_count":11,"is_preprint":false},{"pmid":"16809379","id":"PMC_16809379","title":"Endometrial TIMP-4 mRNA is expressed in the stroma, while TIMP-4 protein accumulates in the epithelium and is released to the uterine fluid.","date":"2006","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/16809379","citation_count":11,"is_preprint":false},{"pmid":"25999146","id":"PMC_25999146","title":"Tissue inhibitor of metalloproteases-4 (TIMP-4) modulates adipocyte differentiation in vitro.","date":"2015","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/25999146","citation_count":11,"is_preprint":false},{"pmid":"33848610","id":"PMC_33848610","title":"CD24 gene inhibition and TIMP-4 gene upregulation by Imperata cylindrica's root extract prevents metastasis of CaSki cells via inhibiting PI3K/Akt/snail signaling pathway and blocking EMT.","date":"2021","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33848610","citation_count":10,"is_preprint":false},{"pmid":"17012332","id":"PMC_17012332","title":"Endometrial expression of the estrogen-sensitive genes MMP-26 and TIMP-4 is altered by a substitution protocol without down-regulation in IVF patients.","date":"2006","source":"Human reproduction (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/17012332","citation_count":9,"is_preprint":false},{"pmid":"38069250","id":"PMC_38069250","title":"Defect of TIMP4 Is Associated with High Myopia and Participates in Rat Ocular Development in a Dose-Dependent Manner.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38069250","citation_count":8,"is_preprint":false},{"pmid":"38398480","id":"PMC_38398480","title":"Expression of Tissue Inhibitors of Metalloproteinases (TIMP-1, TIMP-2, TIMP-3, TIMP-4) in Blood Serum of Patients with Keratoconus.","date":"2024","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38398480","citation_count":7,"is_preprint":false},{"pmid":"29231756","id":"PMC_29231756","title":"Higher levels of circulating TIMP-4 in preeclampsia is strongly associated with clinical parameters and microRNA.","date":"2017","source":"Clinical and experimental hypertension (New York, N.Y. : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/29231756","citation_count":7,"is_preprint":false},{"pmid":"38915119","id":"PMC_38915119","title":"Altered brain expression and cerebrospinal fluid levels of TIMP4 in cerebral amyloid angiopathy.","date":"2024","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/38915119","citation_count":6,"is_preprint":false},{"pmid":"37844423","id":"PMC_37844423","title":"Loss of TIMP3, but not TIMP4, exacerbates thoracic and abdominal aortic aneurysm.","date":"2023","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/37844423","citation_count":6,"is_preprint":false},{"pmid":"35847900","id":"PMC_35847900","title":"Colorectal Cancer Chemotherapy Drug Bevacizumab May Induce Muscle Atrophy Through CDKN1A and TIMP4.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35847900","citation_count":6,"is_preprint":false},{"pmid":"16375928","id":"PMC_16375928","title":"Expression of tissue inhibitor of metalloproteinase-4 (TIMP-4) in endometrium and placenta of rhesus monkey (Macaca mulatta) during early pregnancy.","date":"2005","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16375928","citation_count":6,"is_preprint":false},{"pmid":"36734907","id":"PMC_36734907","title":"Aloperine Prevents Migration, Invasion, and Adhesion by Upregulating TIMP-4 in Human Bladder Cancer Cells.","date":"2023","source":"Protein and peptide letters","url":"https://pubmed.ncbi.nlm.nih.gov/36734907","citation_count":5,"is_preprint":false},{"pmid":"23229788","id":"PMC_23229788","title":"Assessment of the correlation between TIMP4 SNPs and schizophrenia and autism spectrum disorders.","date":"2012","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/23229788","citation_count":4,"is_preprint":false},{"pmid":"27187039","id":"PMC_27187039","title":"TIMP4 Modulates ER-α Signalling in MCF7 Breast Cancer Cells.","date":"2016","source":"Folia biologica","url":"https://pubmed.ncbi.nlm.nih.gov/27187039","citation_count":3,"is_preprint":false},{"pmid":"30697482","id":"PMC_30697482","title":"Association of TIMP4 gene variants with steroid-induced osteonecrosis of the femoral head in the population of northern China.","date":"2019","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/30697482","citation_count":3,"is_preprint":false},{"pmid":"25595263","id":"PMC_25595263","title":"Contribution of TIMP4 rs3755724 polymorphism to susceptibility to focal epilepsy in Malaysian Chinese.","date":"2014","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/25595263","citation_count":3,"is_preprint":false},{"pmid":"41169458","id":"PMC_41169458","title":"TIMP4 as a Potential Complementary Biomarker and Therapeutic Target in Membranous Nephropathy: A Multi-Omics Investigation with Clinical Validation.","date":"2025","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/41169458","citation_count":2,"is_preprint":false},{"pmid":"40269868","id":"PMC_40269868","title":"An integrated machine learning model of transcriptomic genes in multi-center chronic obstructive pulmonary disease reveals the causal role of TIMP4 in airway epithelial cell.","date":"2025","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/40269868","citation_count":2,"is_preprint":false},{"pmid":"24156427","id":"PMC_24156427","title":"[Expression and significance of MMP-26, TIMP-4 and MMP-9 in diffuse large B-cell lymphoma cells].","date":"2013","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/24156427","citation_count":2,"is_preprint":false},{"pmid":"30321788","id":"PMC_30321788","title":"Divergent changes in the content and activity of MMP-26 and TIMP-4 in human umbilical cord tissues associated with preeclampsia.","date":"2018","source":"European journal of obstetrics, gynecology, and reproductive biology","url":"https://pubmed.ncbi.nlm.nih.gov/30321788","citation_count":2,"is_preprint":false},{"pmid":"40418920","id":"PMC_40418920","title":"Exosomal TIMP4 from Myocardial Cell Relieves Heart Failure by Influencing Th17/Treg Balance.","date":"2025","source":"Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/40418920","citation_count":1,"is_preprint":false},{"pmid":"39965635","id":"PMC_39965635","title":"AKAP1-STABILIZED TIMP-4 ATTENUATES ANG-II-INDUCED OXIDATIVE STRESS AND INFLAMMATION IN VASCULAR SMOOTH MUSCLE CELLS BY INACTIVATING THE NF-ΚB SIGNALING.","date":"2025","source":"Shock (Augusta, Ga.)","url":"https://pubmed.ncbi.nlm.nih.gov/39965635","citation_count":1,"is_preprint":false},{"pmid":"12947565","id":"PMC_12947565","title":"[Adenovirus-mediated transfer of TIMP-4 gene inhibits neointimal formation after balloon injury].","date":"2003","source":"Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/12947565","citation_count":1,"is_preprint":false},{"pmid":"21141538","id":"PMC_21141538","title":"[Changing trends of the expression of TIMP-4 in mouse ovary during pregnant and postpartum period].","date":"2008","source":"Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21141538","citation_count":1,"is_preprint":false},{"pmid":"20564221","id":"PMC_20564221","title":"Development of a monoclonal antibody that specifically detects tissue inhibitor of metalloproteinase-4 (TIMP-4) in formalin-fixed, paraffin-embedded human tissues.","date":"2010","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20564221","citation_count":1,"is_preprint":false},{"pmid":"40291774","id":"PMC_40291774","title":"Decreased serum TIMP4 levels in patients with rheumatoid arthritis.","date":"2025","source":"Open life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40291774","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.08.09.607400","title":"Novel Insights into Post-Myocardial Infarction Cardiac Remodeling through Algorithmic Detection of Cell-Type Composition Shifts","date":"2024-08-10","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.09.607400","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":38012,"output_tokens":7771,"usd":0.115301,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17234,"output_tokens":3986,"usd":0.09291,"stage2_stop_reason":"end_turn"},"total_usd":0.208211,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"TIMP-4 binds specifically and with high affinity to the C-terminal hemopexin-like domain (C domain) of human progelatinase A (MMP-2), but not to the fibronectin type II-like collagen-binding domain. This interaction is similar to TIMP-2 binding to progelatinase A, and TIMP-2 and TIMP-4 compete for a common or overlapping binding site on the C domain.\",\n      \"method\": \"Microwell protein binding assay, affinity chromatography, competition binding assay with recombinant domains\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with recombinant proteins, multiple orthogonal binding assays, Kd determination, competition experiments\",\n      \"pmids\": [\"9182583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Recombinant TIMP-4 inhibits MMP-1, MMP-2, MMP-3, MMP-7, and MMP-9 enzymatic activity with IC50 values of 19, 3, 45, 8, and 83 nM, respectively, and inhibits invasion of breast cancer cells across reconstituted basement membranes.\",\n      \"method\": \"Enzymatic kinetic inhibition assays with purified recombinant TIMP-4; Matrigel invasion assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro enzymatic inhibition assays with recombinant protein, multiple MMPs tested, functional invasion assay\",\n      \"pmids\": [\"9252358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TIMP-4, unlike TIMP-2, does not support MT1-MMP-dependent activation of pro-MMP-2 on the cell surface, even though it is an efficient MT1-MMP inhibitor. TIMP-4 lacks the ability to form the TIMP-2-like ternary complex (MT1-MMP·TIMP·pro-MMP-2) required for pro-MMP-2 activation.\",\n      \"method\": \"Cell-based pro-MMP-2 activation assay; Timp2-null cell reconstitution; coexpression of MT1-MMP with TIMP-4 or TIMP-2\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-based functional assay in Timp2-null cells with genetic reconstitution, replicated across two studies (PMID 10998420, 11178970)\",\n      \"pmids\": [\"10998420\", \"11178970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TIMP-4 binds to MT1-MMP and inhibits its autocatalytic turnover/processing on the cell surface. When coexpressed with TIMP-2, TIMP-4 competitively reduces pro-MMP-2 activation by MT1-MMP, suggesting TIMP-4 competes with TIMP-2 for binding to MT1-MMP.\",\n      \"method\": \"Coexpression of MT1-MMP with TIMP-4 and/or TIMP-2 in cells; assessment of MT1-MMP autocatalytic processing and pro-MMP-2 activation by zymography/Western blot\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based coexpression assay, single lab, two functional readouts\",\n      \"pmids\": [\"11178970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TIMP-4 blocks MT1-MMP-mediated activation of pro-MMP-2 (progelatinase A) in human umbilical vein endothelial cells, whereas TIMP-1 does not. TIMP-4 also reduces invasion of U251 glioma cells through Matrigel.\",\n      \"method\": \"Cell-based pro-MMP-2 activation assay with recombinant TIMP-4; Matrigel invasion assay with U87 cells overexpressing TIMP-4\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based functional assays, single lab, two orthogonal functional readouts\",\n      \"pmids\": [\"11437402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Kinetic analysis shows TIMP-4 inhibits MMPs with association rate constants (~10^5 M^-1 s^-1) and Ki values (10^-9 to 10^-12 M) similar to TIMP-1 and TIMP-2. TIMP-4 retains higher inhibitory reactivity with MMPs at acidic pH compared to TIMP-1 and TIMP-2. Biosensor analysis reveals that both pro-MMP-2 and active MMP-2 (with blocked active site) have essentially identical affinities for TIMP-4 via a hemopexin domain site, while active MMP-2 also engages a second lower-affinity site through the catalytic domain.\",\n      \"method\": \"Progress curve kinetic analysis; alpha2-macroglobulin dissociation assay; IAsys biosensor analysis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — rigorous in vitro kinetic reconstitution with recombinant proteins, multiple orthogonal methods (progress curves, dissociation assay, biosensor)\",\n      \"pmids\": [\"12475252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TIMP-4 is the major MMP inhibitor in human platelets (12–16 ng per 10^8 platelets), co-localizes with MMP-2 in resting platelets, and is released upon platelet aggregation induced by collagen and thrombin. Recombinant TIMP-4 (but not TIMP-1) partially inhibits platelet aggregation and recruitment, and this inhibition is potentiated by NO donor GSNO.\",\n      \"method\": \"Western blot, reverse zymography, immunogold electron microscopy, aggregometry, flow cytometry, serotonin release assay\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods, direct functional assays with recombinant TIMP-4, subcellular localization established\",\n      \"pmids\": [\"12466243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The Timp-4 promoter contains an initiator-like element and an Sp1 motif that are essential for expression; mutation of either element almost completely abolishes reporter expression. An inverted CCAAT box acts as a modest repressor (2-fold increase when mutated). The TATA-less promoter is non-inducible by serum.\",\n      \"method\": \"Transient transfection reporter assays with promoter deletion and point mutants in C3H10T1/2 fibroblasts; RACE and RNase protection for transcription start site mapping\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — functional promoter mutagenesis with reporter assays, multiple mutants tested, single lab\",\n      \"pmids\": [\"11988080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TIMP-4 protein accumulates in the adventitia and neointima of rat carotid arteries after balloon injury, and recombinant TIMP-4 reduces invasion of rat vascular smooth muscle cells through matrix-coated membranes by 53%, implicating TIMP-4 in controlling smooth muscle cell migration and collagen deposition after vascular injury.\",\n      \"method\": \"In situ hybridization, immunohistochemistry, Western blot of injured arteries; in vitro Boyden chamber invasion assay with recombinant TIMP-4\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization in vivo with functional consequence validated in vitro, single lab\",\n      \"pmids\": [\"10082471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Adenoviral gene transfer of TIMP-4 into rat carotid arteries after balloon injury inhibits vascular smooth muscle cell migration in vitro and reduces neointimal hyperplasia by 66.5% compared to controls at 28 days.\",\n      \"method\": \"Adenovirus-mediated gene transfer in vivo; monolayer scrape migration assay in vitro; morphometric analysis of neointima/media ratio\",\n      \"journal\": \"Beijing da xue xue bao. Yi xue ban\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct loss/gain-of-function experiment in vivo and in vitro, single lab\",\n      \"pmids\": [\"12947565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The N-terminal domain of TIMP-4 (N-TIMP-4) is a slow tight-binding inhibitor of TACE (ADAM-17) with low nanomolar affinity, whereas full-length TIMP-4 has negligible activity against TACE. Transplantation of three residues (Pro-Phe-Gly) from TIMP-3's AB-loop onto N-TIMP-4 enhanced TACE inhibition 10-fold, indicating the C-terminal domain suppresses and specific AB-loop residues determine TACE activity.\",\n      \"method\": \"Kinetic inhibition assays with recombinant N-TIMP-4 and full-length TIMP-4 against TACE; site-directed mutagenesis of AB-loop and EF-loop\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic assay with mutagenesis identifying specific residues, multiple mutants tested\",\n      \"pmids\": [\"15713681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Timp4-deficient mice (Timp4−/−) generated by homologous recombination show significantly increased post-myocardial infarction mortality primarily due to left ventricular rupture. This enhanced mortality is rescued by a synthetic MMP inhibitor or by genetic deletion of Mmp2, demonstrating that TIMP4 functions as an MMP inhibitor (specifically MMP-2) after myocardial infarction. After cardiac pressure overload, Timp4-deficiency is compensated by increased Timp2 expression with no survival difference.\",\n      \"method\": \"Homologous recombination knockout; myocardial infarction model; aortic banding model; synthetic MMP inhibitor treatment; genetic cross with Mmp2-/- mice; cardiac function assessment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (Timp4-/- × Mmp2-/- double knockout rescue), replicated by pharmacological rescue, multiple disease models\",\n      \"pmids\": [\"20516072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"MMP-9 treatment of primary cardiomyocytes attenuates voltage-induced contraction and reduces Ca2+ transients; TIMP-4 (an MMP-9 inhibitor) reverses this inhibition, and this MMP-9 effect is mediated through PAR-1 signaling. MMP-9 knockout cardiomyocytes contract more rapidly and release more Ca2+ than controls, associated with induction of serca-2a.\",\n      \"method\": \"Primary cardiomyocyte isolation; video-edge detection contractility assay; Fura-2-AM calcium imaging; MMP-9 KO mice; PAR-1 antagonist; recombinant TIMP-4 treatment\",\n      \"journal\": \"Cell biochemistry and biophysics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional assay with recombinant TIMP-4 in primary cells, MMP-9 KO confirmation, single lab\",\n      \"pmids\": [\"20422465\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Hypoxia upregulates TIMP-4 (and TIMP-3) in fetal rat hearts and H9c2 cardiomyocytes. Knockdown of TIMP-4 completely abrogates hypoxia-mediated inhibition of cardiomyocyte proliferation (Ki-67, BrdU, cyclin D2), while having no significant effect on basal proliferation, establishing a causal role for TIMP-4 in hypoxia-induced inhibition of cardiomyocyte proliferation.\",\n      \"method\": \"siRNA knockdown of TIMP-4 in H9c2 cells; Ki-67 immunostaining; BrdU incorporation; Western blot for cyclin D2 and p27; ex vivo fetal heart hypoxia model\",\n      \"journal\": \"American journal of physiology. Regulatory, integrative and comparative physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA loss-of-function with specific proliferation readouts, two model systems, single lab\",\n      \"pmids\": [\"23427085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TIMP-4 overexpression in cervical cancer cells enriches the tumor progenitor cell (TPC) population and accelerates xenograft tumor growth. Genome-wide expression analysis shows hrTIMP-4 treatment activates NFκB signaling pathway globally, modulating cell survival, proliferation, inflammation, and EMT networks.\",\n      \"method\": \"Stable TIMP-4 overexpression; xenograft limiting dilution assay; recombinant TIMP-4 treatment; microarray gene expression; in silico pathway analysis; NFκB pathway validation\",\n      \"journal\": \"Molecular carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — stable gain-of-function with in vivo and in vitro readouts, pathway analysis, single lab\",\n      \"pmids\": [\"26618609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TIMP-4 knockdown in 3T3-L1 preadipocytes accelerates differentiation into mature adipocytes, associated with decreased NFκB activity during adipogenesis, suggesting TIMP-4 acts as a negative regulator of adipogenesis via NFκB modulation.\",\n      \"method\": \"Stable shRNA knockdown in 3T3-L1 cells; adipocyte differentiation assay; microarray gene expression; NFκB activity assay\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — stable loss-of-function with functional differentiation readout and pathway identification, single lab\",\n      \"pmids\": [\"25999146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"LOX (lysyl oxidase) transcriptionally activates the SNAI2 promoter, and LOX/SNAI2 depletion reduces TIMP4 secretion in cancer cell lines. LOX binds to the SNAI2 promoter as shown by chromatin immunoprecipitation, placing TIMP4 downstream of a LOX-SNAI2 axis.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP); promoter luciferase assay; siRNA knockdown; protein array for MMPs/TIMPs; in vivo metastatic mouse model\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and luciferase assays establish LOX→SNAI2 axis, TIMP4 secretion downstream confirmed by array, single lab\",\n      \"pmids\": [\"27029493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Recombinant TIMP-4 treatment of MCF7 breast cancer cells activates ER-α signaling (increases ER-α protein levels) and enriches for ER-α binding sites in promoters of TIMP4-upregulated genes. TIMP-4 also modulates HIF1A and TGF-β signaling while downregulating FOXO3 signaling.\",\n      \"method\": \"Recombinant TIMP-4 treatment; RNASeq; RT-PCR validation; network pathway analysis\",\n      \"journal\": \"Folia biologica\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — transcriptomic analysis after recombinant protein treatment, single method, single lab, limited mechanistic follow-up\",\n      \"pmids\": [\"27187039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Absence of TIMP4 in knockout mice impairs lipid absorption on high-fat diet by preventing proteolytic processing of CD36 protein in intestinal enterocytes. HFD increases CD36 protein (not mRNA) in WT but not Timp4-/- intestinal enterocytes, indicating TIMP4 regulates CD36 post-translationally through metalloproteinase-dependent mechanisms.\",\n      \"method\": \"Timp4 knockout mice; high-fat diet model; CD36 protein and mRNA quantification in intestinal enterocytes; lipid absorption (fecal free fatty acid); body composition analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with post-translational mechanism inference (protein/mRNA dissociation), single lab, multiple readouts\",\n      \"pmids\": [\"28740132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CRN2 (an actin filament binding protein) directly binds TIMP4 and MMP14 (MT1-MMP) as novel binding partners; all three proteins co-localize at lamellipodia fronts. CRN2 increases TIMP4 secretion and enhances MMP14 catalytic activity, promoting perivascular invasion of glioblastoma cells.\",\n      \"method\": \"Immunoprecipitation; pull-down assays; enzyme activity assay; immunofluorescence co-localization; CRN2 knockout mouse model; transplanted glioblastoma cell assay\",\n      \"journal\": \"European journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP/pulldown with functional readout (secretion, enzyme activity), single lab\",\n      \"pmids\": [\"31677819\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TGF-β1 stimulation of isolated human atrial fibroblasts directly suppresses TIMP-4 protein levels as shown by Western blot. In patients with atrial fibrillation secondary to rheumatic heart disease, TIMP-4 expression is inversely correlated with TGF-β1 levels (r = -0.98), and lower TIMP-4 correlates with increased MMP-2, collagen I, and collagen III.\",\n      \"method\": \"In vitro recombinant TGF-β1 stimulation of primary atrial fibroblasts; Western blot; patient tissue Western blot and qRT-PCR; Masson staining\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in vitro stimulation assay plus clinical tissue correlation, single lab\",\n      \"pmids\": [\"25971370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"EZH2 suppresses Timp4 gene transcription by catalyzing H3K27me3 modifications in the Timp4 promoter region. Knockdown of Ezh2 increases Timp4 expression and accelerates replicative senescence of atrial fibroblasts; Ezh2 overexpression reduces senescence. A functional balance between TIMP4 and MMP8 in atrial fibroblasts is disrupted by Ezh2 level changes.\",\n      \"method\": \"ChIP assay for H3K27me3 at Timp4 promoter; siRNA knockdown and overexpression of Ezh2; senescence assays; RNA-seq; GSK-126 and GSK-343 methyltransferase inhibitors\",\n      \"journal\": \"Journal of inflammation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP establishes direct epigenetic mark on Timp4 promoter, gain/loss-of-function with functional readout, single lab\",\n      \"pmids\": [\"35996686\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"miR-146b-5p directly targets and represses TIMP4 in atrial cardiomyocytes; reduced TIMP4 increases MMP9 activity and collagen synthesis. Inhibition of miR-146b-5p in a MI mouse model increases TIMP4 expression and reduces cardiac fibrosis markers (MMP9, TGFB1, COL1A1).\",\n      \"method\": \"miR-146b-5p transfection in hiPSC-aCMs-fibroblast co-culture; antagomiR-146 treatment in MI mouse model; Western blot and qRT-PCR for TIMP4/MMP9/TGFB1/COL1A1\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — miRNA overexpression/inhibition with functional collagen/MMP readout in vitro and in vivo, single lab\",\n      \"pmids\": [\"34643044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Loss of TIMP4 does not exacerbate thoracic or abdominal aortic aneurysm severity compared to wild-type mice, whereas loss of TIMP3 significantly worsens both. In vitro, Timp4 knockdown does not significantly compromise endothelial monolayer permeability compared to Timp3 knockdown.\",\n      \"method\": \"Timp4-/- and Timp3-/- mouse aortic aneurysm models (elastase); histology; proteinase activity; EC monolayer permeability assay\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — negative finding for TIMP4 in aneurysm established by KO experiment, provides pathway context; single lab\",\n      \"pmids\": [\"37844423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TIMP4 promoter CpG islands undergo methylation during heart failure progression (created by AV fistula), leading to epigenetic silencing of TIMP4 expression. Upregulation of miR-122a also contributes to TIMP4 regulation. Consequent MMP9 upregulation drives cardiac remodeling.\",\n      \"method\": \"Methylation-specific PCR; high-resolution melting; bisulfite sequencing; ChIP for histone modifications; miRNA expression analysis; AV fistula heart failure mouse model; echocardiography\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methylation assays plus ChIP establish epigenetic mechanism, single lab\",\n      \"pmids\": [\"27396717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"AKAP1 (RNA binding protein) stabilizes TIMP-4 mRNA to maintain TIMP-4 expression. TIMP-4 upregulation suppresses Ang-II-induced NF-κB pathway activation, oxidative stress, inflammation, and MMP9 expression in vascular smooth muscle cells. TIMP-4 reduction partially abrogates AKAP1's suppressive effects, placing TIMP-4 downstream of AKAP1 in protection against VSMC injury.\",\n      \"method\": \"RNA immunoprecipitation (RIP); mRNA stability analysis; TIMP-4 overexpression and knockdown in VSMCs; Western blot for NF-κB signaling; oxidative stress and inflammation assays; GSE7084 and GSE140947 dataset analysis\",\n      \"journal\": \"Shock (Augusta, Ga.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RIP establishes AKAP1-TIMP4 mRNA interaction, gain/loss-of-function with NF-κB pathway readout, single lab\",\n      \"pmids\": [\"39965635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TIMP4 heterozygous loss-of-function variants (c.528C>A and c.234_235insAA) are enriched in early-onset high myopia patients. Timp4-deficient rats show axial length elongation, reduced retinal and scleral collagen content, and reduced retinal thickness in a dose-dependent manner (Timp4-/- < Timp4+/- < Timp4+/+), establishing a causal role for TIMP4 in maintaining ocular ECM homeostasis and normal ocular development.\",\n      \"method\": \"Whole exome sequencing; Timp4 gene-editing rat model; ocular morphology and axial length measurement; electroretinogram; HE and immunofluorescence staining; collagen quantification; form deprivation myopia model\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO rat model with dose-dependent phenotype and multiple ocular readouts, supported by human genetic data, single lab\",\n      \"pmids\": [\"38069250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In human endometrium, TIMP-4 mRNA is exclusively produced in stromal cells, while TIMP-4 protein is taken up by epithelial cells, accumulates in apical granules, and is secreted into uterine fluid. TIMP-4 is the main TIMP present in uterine fluid. This stromal-to-epithelial transcytosis pathway establishes compartment-specific regulation of MMP-26 activity.\",\n      \"method\": \"In situ hybridization; immunohistochemistry; real-time PCR on separated stromal and epithelial cells; Western blot of uterine fluid\",\n      \"journal\": \"Molecular human reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct subcellular localization in separated cell populations with functional implications, single lab\",\n      \"pmids\": [\"16809379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Osteoprotegerin (OPG) upregulates TIMP-4 expression while downregulating ADAMTS-5 in chondrocytes via MEK/ERK signaling; suppression of ERK by PD098059 blocks OPG-induced TIMP-4 upregulation. OPG had no effect on TIMP-1, TIMP-2, or TIMP-3 expression, showing specificity for TIMP-4.\",\n      \"method\": \"Primary rat chondrocyte culture; OPG treatment; MEK/ERK inhibitors (U0126, PD098059); Western blot; qPCR\",\n      \"journal\": \"Molecular medicine reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway inhibitor experiments establish MEK/ERK as upstream of TIMP-4 regulation, specific to TIMP-4 vs other TIMPs, single lab\",\n      \"pmids\": [\"24126801\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TIMP-4 is a secreted metalloproteinase inhibitor that directly inhibits MMP-1, -2, -3, -7, -9, and MT1-MMP (MMP-14), and weakly inhibits TACE (ADAM-17) only in its N-terminal domain form; it binds the hemopexin C-domain of pro-MMP-2 (similar to TIMP-2) but, unlike TIMP-2, cannot form the ternary MT1-MMP·TIMP·pro-MMP-2 complex required for pro-MMP-2 activation and instead competitively inhibits this process; in the heart it is essential post-myocardial infarction through MMP-2 inhibition (rescued by MMP-2 deletion), is epigenetically silenced by promoter CpG methylation (via Ezh2/H3K27me3) and miR-122a in heart failure, and regulates immune balance via exosomal delivery; it controls vascular smooth muscle cell migration and neointimal formation after injury; in platelets it is the dominant MMP inhibitor and modulates aggregation; its expression is transcriptionally driven by an Sp1/initiator element, regulated downstream of LOX-SNAI2, suppressed by TGF-β1, and its mRNA is stabilized by AKAP1; in adipocytes and cardiomyocytes TIMP-4 acts as a negative regulator of differentiation/proliferation partly through NFκB signaling; and its loss disrupts CD36 proteolytic processing in intestinal enterocytes to impair lipid absorption.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TIMP4 is a secreted tissue inhibitor of metalloproteinases that restrains MMP-driven extracellular matrix turnover across cardiovascular, vascular, reproductive, and ocular tissues [#1, #11]. It is a broad-spectrum, high-affinity inhibitor of soluble MMPs (MMP-1, -2, -3, -7, -9) with low-nanomolar potency [#1, #5], and binds the C-terminal hemopexin-like domain of pro-MMP-2 at a site overlapping that of TIMP-2 [#0, #5]. Despite being an efficient MT1-MMP inhibitor, TIMP-4 cannot assemble the TIMP-2-like ternary MT1-MMP\\u00b7TIMP\\u00b7pro-MMP-2 complex needed for cell-surface pro-MMP-2 activation, and instead competes with TIMP-2 to suppress this activation step [#2, #3, #4]. The inhibitory repertoire is domain-partitioned: only the N-terminal domain inhibits TACE/ADAM-17, an activity suppressed by the C-terminal domain and tunable by AB-loop residues [#10]. In the heart, TIMP4 is essential after myocardial infarction, where its loss causes lethal ventricular rupture that is rescued by Mmp2 deletion, establishing MMP-2 inhibition as its core protective mechanism [#11]. Its expression is governed by an Sp1/initiator-driven TATA-less promoter [#7] and is dynamically controlled by epigenetic silencing through promoter CpG methylation and EZH2/H3K27me3 [#21, #24], by miRNA repression [#22, #24], by suppression downstream of TGF-\\u03b21 [#20], and by mRNA stabilization through AKAP1 [#25]; downstream, TIMP-4 modulates NF\\u03baB signaling in vascular smooth muscle cells and during adipogenesis [#15, #25]. Beyond MMP inhibition, TIMP4 controls vascular smooth muscle cell migration and neointimal formation after injury [#8, #9], regulates CD36 proteolytic processing in enterocytes to enable lipid absorption [#18], and maintains ocular ECM homeostasis, with heterozygous loss-of-function variants linked to early-onset high myopia [#26].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established that TIMP-4 is a functional MMP inhibitor and defined its physical interaction with pro-MMP-2, answering whether the protein behaves like other TIMPs.\",\n      \"evidence\": \"Recombinant binding/competition assays with MMP-2 domains and enzymatic inhibition assays plus a Matrigel invasion readout\",\n      \"pmids\": [\"9182583\", \"9252358\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Inhibitory profile against membrane-type MMPs not yet tested\", \"No in vivo confirmation of inhibitory function\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Resolved why TIMP-4 differs functionally from TIMP-2 despite similar binding, showing it inhibits MT1-MMP but cannot support ternary-complex-dependent pro-MMP-2 activation.\",\n      \"evidence\": \"Cell-based pro-MMP-2 activation assays in Timp2-null cells with MT1-MMP/TIMP coexpression\",\n      \"pmids\": [\"10998420\", \"11178970\", \"11437402\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for the failure to form the ternary complex not defined\", \"Competition with TIMP-2 quantified only in overexpression systems\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Provided rigorous kinetic constants and a two-site binding model, and identified platelets as a major physiological compartment for TIMP-4.\",\n      \"evidence\": \"Progress-curve kinetics and biosensor analysis with recombinant proteins; platelet biochemistry, electron microscopy and aggregometry\",\n      \"pmids\": [\"12475252\", \"12466243\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of the acidic-pH reactivity not established\", \"Mechanism of TIMP-4 effect on platelet aggregation beyond MMP inhibition unclear\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined the cis-elements controlling TIMP4 transcription, answering how the gene is constitutively expressed.\",\n      \"evidence\": \"Promoter deletion/point-mutant reporter assays and transcription start site mapping in fibroblasts\",\n      \"pmids\": [\"11988080\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trans-acting factors beyond Sp1 not identified\", \"No link yet to tissue-specific or signal-driven regulation\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Mapped the domain determinants of TIMP-4 target specificity, showing the N-terminal domain alone inhibits TACE and that the C-terminal domain suppresses this.\",\n      \"evidence\": \"Kinetic inhibition assays of N-TIMP-4 versus full-length TIMP-4 against TACE with AB/EF-loop mutagenesis\",\n      \"pmids\": [\"15713681\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of TACE inhibition by an N-terminal fragment in vivo unknown\", \"Whether full-length TIMP-4 ever exposes this activity in tissue not addressed\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated the essential, MMP-2-specific cardioprotective role of TIMP4 in vivo through genetic epistasis, the strongest causal anchor for its function.\",\n      \"evidence\": \"Timp4 knockout mice in MI and pressure-overload models with pharmacological and Mmp2-deletion rescue; primary cardiomyocyte contractility assays\",\n      \"pmids\": [\"20516072\", \"20422465\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other tissues show MMP-2-specific dependence not tested\", \"Compensation by TIMP-2 leaves the unique role outside the heart unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established that TIMP4 expression is dynamically silenced in cardiac and vascular disease through layered epigenetic and post-transcriptional mechanisms.\",\n      \"evidence\": \"Methylation-specific PCR, bisulfite sequencing, ChIP for H3K27me3, miRNA profiling and EZH2 gain/loss-of-function in heart-failure and atrial-fibroblast models\",\n      \"pmids\": [\"27396717\", \"35996686\", \"34643044\", \"25971370\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal hierarchy among methylation, EZH2, and miRNAs not resolved\", \"Most mechanisms shown in single labs and rodent models\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Extended TIMP4 function beyond MMP inhibition to metabolic physiology, showing it is required for CD36 proteolytic processing and intestinal lipid absorption.\",\n      \"evidence\": \"Timp4 knockout mice on high-fat diet with CD36 protein/mRNA dissociation and lipid absorption measurements\",\n      \"pmids\": [\"28740132\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The specific metalloproteinase mediating CD36 processing not identified\", \"Direct enzymatic mechanism linking TIMP-4 to CD36 not reconstituted\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified a direct protein partner (CRN2) linking TIMP-4 and MT1-MMP at the invasive front, suggesting spatial coordination of inhibitor and protease.\",\n      \"evidence\": \"Reciprocal Co-IP/pull-down, enzyme activity assays and co-localization in glioblastoma cells with a CRN2 knockout model\",\n      \"pmids\": [\"31677819\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; reciprocal validation not extended to other systems\", \"Functional consequence of the CRN2-TIMP4 interaction on inhibitory activity unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Connected TIMP4 to a human Mendelian-like phenotype, establishing a causal role in ocular ECM homeostasis.\",\n      \"evidence\": \"Whole-exome sequencing of high-myopia patients plus dose-dependent Timp4-deficient rat ocular phenotyping\",\n      \"pmids\": [\"38069250\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular target whose dysregulation drives scleral/retinal collagen loss not defined\", \"Human variants are heterozygous; full penetrance and mechanism not established\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined an mRNA-stabilizing upstream regulator (AKAP1) and placed TIMP-4 as a node suppressing NF\\u03baB-driven vascular injury responses.\",\n      \"evidence\": \"RNA immunoprecipitation, mRNA stability assays and TIMP-4 gain/loss-of-function with NF\\u03baB pathway readouts in VSMCs\",\n      \"pmids\": [\"39965635\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mechanism of NF\\u03baB suppression by TIMP-4 not resolved\", \"Single lab; in vivo confirmation of the AKAP1-TIMP4 axis lacking\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How TIMP-4's varied non-canonical activities (CD36 processing, NF\\u03baB modulation, platelet and ocular roles) connect mechanistically to its core metalloproteinase-inhibitory function remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model explaining ternary-complex failure versus TIMP-2\", \"Tissue-specific MMP substrates downstream of TIMP-4 largely uncharacterized\", \"Whether NF\\u03baB and metabolic effects are protease-dependent unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008191\", \"supporting_discovery_ids\": [1, 5]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 5, 11]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [6, 27]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [8, 26]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [15, 25]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"MMP2\", \"MMP14\", \"TIMP2\", \"ADAM17\", \"MMP9\", \"CRN2\", \"AKAP1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}